

# Eric J Small

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8708809/publications.pdf>

Version: 2024-02-01

86  
papers

18,082  
citations

109321

35  
h-index

71685

76  
g-index

87  
all docs

87  
docs citations

87  
times ranked

16652  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 411-422.	27.0	4,724
2	Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 1513-1520.	27.0	3,344
3	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. <i>New England Journal of Medicine</i> , 2013, 368, 138-148.	27.0	2,412
4	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016, 34, 1402-1418.	1.6	1,089
5	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 479-505.	4.9	943
6	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 591-597.	1.6	584
7	Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2492-2503.	1.6	477
8	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. <i>Cell</i> , 2018, 174, 758-769.e9.	28.9	459
9	Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2315-2324.	7.0	407
10	Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1652-1659.	1.6	332
11	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	288
12	Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP Inhibitors. <i>Cancer Discovery</i> , 2017, 7, 999-1005.	9.4	223
13	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. <i>Clinical Cancer Research</i> , 2019, 25, 6916-6924.	7.0	200
14	The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , 2020, 52, 778-789.	21.4	198
15	Ketoconazole Retains Activity in Advanced Prostate Cancer Patients with Progression Despite Flutamide Withdrawal. <i>Journal of Urology</i> , 1997, 157, 1204-1207.	0.4	193
16	Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone. <i>Journal of Clinical Oncology</i> , 2000, 18, 1440-1450.	1.6	176
17	Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	163
18	The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. <i>Cancer</i> , 1995, 76, 1428-1434.	4.1	162

#	ARTICLE	IF	CITATIONS
19	Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. <i>Journal of Clinical Oncology</i> , 2015, 33, 1356-1363.	1.6	120
20	Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 562-571.	1.9	104
21	Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. <i>Journal of Clinical Oncology</i> , 2019, 37, 403-410.	1.6	83
22	HER2 Protein Expression and Gene Amplification in Androgen-Independent Prostate Cancer. <i>American Journal of Clinical Pathology</i> , 2001, 116, 234-239.	0.7	70
23	Hyperpolarized <sup>13</sup> C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 269-276.	3.9	68
24	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 531-538.	3.9	66
25	Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. <i>European Urology</i> , 2020, 77, 333-341.	1.9	65
26	Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3042-3050.	1.6	60
27	Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. <i>Clinical Cancer Research</i> , 2019, 25, 2450-2457.	7.0	52
28	Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. <i>Molecular Cancer Research</i> , 2019, 17, 1235-1240.	3.4	51
29	The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021, 12, 7349.	12.8	51
30	Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. <i>Cancer Immunology Research</i> , 2015, 3, 1008-1016.	3.4	49
31	Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. <i>Clinical Cancer Research</i> , 2016, 22, 4890-4900.	7.0	46
32	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , 2020, 1, 1041-1053.	13.2	45
33	The Case for Secondary Hormonal Therapies in the Chemotherapy Age. <i>Journal of Urology</i> , 2006, 176, S66-71.	0.4	37
34	Nephrectomy for metastatic renal cell carcinoma: A component of systemic treatment regimens. <i>Journal of Surgical Oncology</i> , 1994, 55, 7-13.	1.7	36
35	Phase I Study of CTT1057, an <sup>18</sup> F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 910-916.	5.0	35
36	Overview of bladder cancer trials in the Cancer and Leukemia Group B. <i>Cancer</i> , 2003, 97, 2090-2098.	4.1	33

#	ARTICLE	IF	CITATIONS
37	A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2016, 18, 946-951.	2.6	33
38	CTâ€“Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1073-1081.e1.	0.5	30
39	The Treatment of Advanced Prostate Cancer with Ketoconazole. <i>Drug Safety</i> , 1999, 20, 451-458.	3.2	28
40	Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. <i>Molecular Cancer Research</i> , 2017, 15, 1221-1229.	3.4	27
41	An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. <i>Cancer Letters</i> , 2016, 380, 144-152.	7.2	26
42	Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 625-633.	2.4	24
43	A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. , 1996, 78, 1775-1780.		23
44	Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. <i>Oncotarget</i> , 2017, 8, 71447-71455.	1.8	23
45	Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. , 2021, 9, e002254.		21
46	Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 1644.	7.1	21
47	Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2000, 88, 1310-1316.	4.1	19
48	An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer. <i>Nature Communications</i> , 2021, 12, 4601.	12.8	18
49	Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors. <i>Future Oncology</i> , 2019, 15, 2337-2348.	2.4	15
50	Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e180-e189.	1.9	15
51	Differential treatment outcomes in <i>BRCA1/2</i> , <i>CDK12</i> , and <i>ATM</i> mutated metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2021, 127, 1965-1973.	4.1	15
52	Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 184-190.e2.	1.9	13
53	Accelerating cancer clinical trial recruitment through a financial reimbursement program integrated with patient navigation: an interrupted time series analysis. <i>Journal of Cancer Policy</i> , 2021, 30, 100305.	1.4	13
54	Pyrazoloacridine for the Treatment of Hormone-Refractory Prostate Cancer. <i>Cancer Investigation</i> , 1998, 16, 456-461.	1.3	12

#	ARTICLE	IF	CITATIONS
55	Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundationâ€œSupported West Coast Prostate Cancer Dream Team. European Urology Focus, 2016, 2, 469-471.	3.1	12
56	Hormonal treatment for prostate cancer. Expert Opinion on Investigational Drugs, 2001, 10, 493-510.	4.1	10
57	Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. Therapeutic Advances in Urology, 2018, 10, 445-454.	2.0	10
58	How current reporting practices may mask differences: A call for examining cancer-specific demographic enrollment patterns in cancer treatment clinical trials. Contemporary Clinical Trials Communications, 2019, 16, 100476.	1.1	10
59	CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. Clinical Cancer Research, 2022, 28, 3066-3075.	7.0	10
60	Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. Clinical Genitourinary Cancer, 2015, 13, e191-e198.	1.9	9
61	Outpatient combination chemoimmunotherapy for patients with metastatic melanoma. , 1999, 86, 2160-2165.		8
62	Does the COVID-19 outbreak identify a broader need for an urgent transformation of cancer clinical trials research?. Contemporary Clinical Trials, 2020, 92, 105997.	1.8	8
63	Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNÎ± ± Bevacizumab: Results from CALGB 90206 (Alliance). Clinical Cancer Research, 2022, 28, 2771-2778.	7.0	8
64	A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 149.e7-149.e13.	1.6	7
65	A step towards equitable clinical trial recruitment: a protocol for the development and preliminary testing of an online prostate cancer health information and clinical trial matching tool. Pilot and Feasibility Studies, 2019, 5, 123.	1.2	7
66	Implementation of a Multisite Financial Reimbursement Program in Cancer Clinical Trials Integrated With Patient Navigation: A Pilot Randomized Clinical Trial. JCO Oncology Practice, 2022, 18, e915-e924.	2.9	7
67	Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials. Cancer, 2018, 124, 1383-1390.	4.1	6
68	Serum Prostate Specific Antigen as a Predictor of Survival in Prostate Cancer Patients Treated with Second-Line Hormonal Therapy (CALGB 9181). Prostate Journal, 2001, 3, 18-25.	0.2	5
69	Prospects for the use of ipilimumab in treating advanced prostate cancer. Expert Opinion on Biological Therapy, 2016, 16, 421-432.	3.1	5
70	Apalutamide and its use in the treatment of prostate cancer. Future Oncology, 2019, 15, 591-599.	2.4	5
71	Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 931.e9-931.e16.	1.6	4
72	OUP accepted manuscript. Oncologist, 2022, , .	3.7	4

#	ARTICLE	IF	CITATIONS
73	A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma. <i>Cancer</i> , 1994, 73, 2803-2807.	4.1	2
74	Examining reporting and representation of patients with cancer in COVID-19 clinical trials. <i>Cancer Reports</i> , 2021, 4, e1355.	1.4	2
75	Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality. <i>Cancer</i> , 2021, 127, 2623-2630.	4.1	2
76	A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 730.e9-730.e15.	1.6	2
77	The relationship between symptomatology and treatment selection in metastatic castrate-resistant prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 1-15.	0.3	2
78	Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa003.	2.9	1
79	Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance). <i>Journal of Urology</i> , 2021, 206, 319-324.	0.4	1
80	Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. <i>JCO Oncology Practice</i> , 2021, , OP2100480.	2.9	1
81	Re: Prostate Specific Antigen after Gonadal Androgen Withdrawal and Deferred Flutamide Treatment. <i>Journal of Urology</i> , 1996, 155, 1704-1705.	0.4	0
82	Therapy of Advanced Prostate Cancer: Part I: Antiandrogen Withdrawal, Androgen Receptor Mutations, and Secondary Hormonal Manipulations. <i>Prostate Journal</i> , 2000, 2, 116-122.	0.2	0
83	Therapy of Advanced Prostate Cancer Part II: Response End Points and the Use of Chemotherapy. <i>Prostate Journal</i> , 2000, 2, 173-178.	0.2	0
84	Immunotherapy for Prostate Cancer. <i>American Journal of Cancer</i> , 2006, 5, 331-339.	0.4	0
85	Reply to A. Dalla Volta et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 351-352.	1.6	0
86	Mobile Clinical Trial Matching Technology in Medical Oncology Clinic: A Pilot Feasibility Study. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100182.	2.1	0